The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases
Tóm tắt
The extracellular domains of cytokine receptors are released during inflammation, but little is known about the shedding of Toll-like receptors (TLR) and whether they can be used as diagnostic biomarkers. The release of sTLR2 and sTLR4 was studied in in-vitro stimulations, as well as in-vivo during experimental human endotoxemia (n = 11, 2 ng/kg LPS), and in plasma of 394 patients with infections (infectious mononucleosis, measles, respiratory tract infections, bacterial sepsis and candidemia) or non-infectious inflammation (Crohn’s disease, gout, rheumatoid arthritis, autoinflammatory syndromes and pancreatitis). Using C-statistics, the value of sTLR2 and sTLR4 levels for discrimination between infections and non-infectious inflammatory diseases, as well as between viral and bacterial infections was analyzed. In-vitro, peripheral blood mononuclear cells released sTLR2 and sTLR4 by exposure to microbial ligands. During experimental human endotoxemia, plasma concentrations peaked after 2 hours (sTLR4) and 4 hours (sTLR2). sTLR4 did not correlate with cytokines, but sTLR2 correlated positively with TNFα (rs = 0.80, P < 0.05), IL-6 (rs = 0.65, P < 0.05), and IL-1Ra (rs = 0.57, P = 0.06), and negatively with IL-10 (rs = -0.58, P = 0.06), respectively. sTLR4 had a similar area under the ROC curve [AUC] for differentiating infectious and non-infectious inflammation compared to CRP: 0.72 (95% CI 0.66-0.79) versus 0.74 (95% CI 0.69-0.80) [P = 0.80], while sTLR2 had a lower AUC: 0.60 (95% CI 0.54-0.66) [P = 0.0004]. CRP differentiated bacterial infections better from viral infections than sTLR2 and sTLR4: AUC 0.94 (95% CI 0.90-0.96) versus 0.58 (95% CI 0.51-0.64) and 0.75 (95% CI 0.70-0.80), respectively [P < 0.0001 for both]. sTLRs are released into the circulation, and suggest the possibility to use sTLRs as diagnostic tool in inflammatory conditions.
Tài liệu tham khảo
Liew FY, Xu D, Brint EK, O’Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005, 5: 446-458. 10.1038/nri1630.
Cook DN, Pisetsky DS, Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004, 5: 975-979. 10.1038/ni1116.
Heaney ML, Golde DW: Soluble cytokine receptors. Blood. 1996, 87: 847-857.
LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, Griffin GE, Ferrara P, Schiffrin EJ, Morgan BP, Labeta MO: Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol. 2003, 171: 6680-6689. 10.4049/jimmunol.171.12.6680.
Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y: Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol. 2000, 165: 6682-6686. 10.4049/jimmunol.165.12.6682.
Dulay AT, Buhimschi CS, Zhao G, Oliver EA, Mbele A, Jing S, Buhimschi IA: Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J Immunol. 2009, 182: 7244-7253. 10.4049/jimmunol.0803517.
Kuroishi T, Tanaka Y, Sakai A, Sugawara Y, Komine K, Sugawara S: Human parotid saliva contains soluble toll-like receptor (TLR) 2 and modulates TLR2-mediated interleukin-8 production by monocytic cells. Mol Immunol. 2007, 44: 1969-1976. 10.1016/j.molimm.2006.09.028.
Yang HB, Xie KQ, Deng JM, Qin SM: Expression of soluble Toll-like receptors in pleural effusions. Chin Med J (Engl). 2010, 123: 2225-2230.
Kacerovsky M, Andrys C, Drahosova M, Musilova I, Hornychova H, Lesko D, Tosner J, Jacobsson B: Soluble Toll-like receptor 1 family members in the amniotic fluid of women with preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med. 2012, 25: 1699-1704. 10.3109/14767058.2012.658463.
Kacerovsky M, Andrys C, Hornychova H, Pliskova L, Lancz K, Musilova I, Drahosova M, Bolehovska R, Tambor V, Jacobsson B: Amniotic fluid soluble Toll-like receptor 4 in pregnancies complicated by preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med. 2012, 25: 1148-1155. 10.3109/14767058.2011.626821.
Ubenauf KM, Krueger M, Henneke P, Berner R: Lipopolysaccharide binding protein is a potential marker for invasive bacterial infections in children. Pediatr Infect Dis J. 2007, 26: 159-162. 10.1097/01.inf.0000253064.88722.6d.
Chalupa P, Beran O, Herwald H, Kasprikova N, Holub M: Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection. 2011, 39: 411-417. 10.1007/s15010-011-0126-4.
Andrys C, Kacerovsky M, Drahosova M, Musilova I, Pliskova L, Hornychova H, Prochazka M, Jacobsson B: Amniotic fluid soluble Toll-like receptor 2 in pregnancies complicated by preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2013, 26: 520-527. 10.3109/14767058.2012.741634.
Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, Hoedemaekers CW, Pickkers P: Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Crit Care Med. 2011, 39: 1866-1870. 10.1097/CCM.0b013e3182190d5d.
ten Oever J, Riza A, Sabou M, Cismaru C, Netea MG, Slavcovici A: Characterization of the acute inflammatory response in measles infection. J Ped Infect Dis. 2014, 3: 197-200.
van de Veerdonk FL, Wever PC, Hermans MH, Fijnheer R, Joosten LA, van der Meer JW, Netea MG, Schneeberger PM: IL-18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity. J Infect Dis. 2012, 206: 197-201. 10.1093/infdis/jis335.
Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, Atmatzidis S, Chrisofos M, Evangelopoulou V, Frantzeskaki F, Giannopoulos P, Giannikopoulos G, Gialvalis D, Gourgoulis GM, Kotzampassi K, Katsifa K, Kofinas G, Kontopidou F, Koratzanis G, Koulouras V, Koutsikou A, Koupetori M, Kritselis I, Leonidou L, Mega A, Mylona V, Nikolaou H, Orfanos S, Panagopoulos P, Paramythiotou E, et al.: Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect. 2011, 77: 58-63. 10.1016/j.jhin.2010.07.026.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.
Johnson MD, Plantinga TS, van de Vosse E, Velez Edwards DR, Smith PB, Alexander BD, Yang JC, Kremer D, Laird GM, Oosting M, Joosten LA, van der Meer JW, van Dissel JT, Walsh TJ, Perfect JR, Kullberg BJ, Scott WK, Netea MG: Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis. 2012, 54: 502-510. 10.1093/cid/cir827.
Mylona V, Koussoulas V, Tzivras D, Makrygiannis E, Georgopoulou P, Koratzanis G, Giamarellos-Bourboulis EJ, Tzivras MD: Changes in adaptive and innate immunity in patients with acute pancreatitis and systemic inflammatory response syndrome. Pancreatology. 2011, 11: 475-481. 10.1159/000329460.
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48. 10.1002/art.1780380107.
DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.
Zunt SL, Burton LV, Goldblatt LI, Dobbins EE, Srinivasan M: Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells. Clin Exp Immunol. 2009, 156: 285-293. 10.1111/j.1365-2249.2009.03854.x.
Raby AC, Le Bouder E, Colmont C, Davies J, Richards P, Coles B, George CH, Jones SA, Brennan P, Topley N, Labeta MO: Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol. 2009, 183: 506-517. 10.4049/jimmunol.0802909.
Hyakushima N, Mitsuzawa H, Nishitani C, Sano H, Kuronuma K, Konishi M, Himi T, Miyake K, Kuroki Y: Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J Immunol. 2004, 173: 6949-6954. 10.4049/jimmunol.173.11.6949.
Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P, Jenkins BJ: STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012, 22: 466-478. 10.1016/j.ccr.2012.08.010.
Marsik C, Mayr F, Cardona F, Derhaschnig U, Wagner OF, Jilma B: Endotoxaemia modulates Toll-like receptors on leucocytes in humans. Br J Haematol. 2003, 121: 653-656. 10.1046/j.1365-2141.2003.04350.x.
Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O: Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005, 83: 196-198. 10.1111/j.1440-1711.2005.01314.x.
Hayashi F, Means TK, Luster AD: Toll-like receptors stimulate human neutrophil function. Blood. 2003, 102: 2660-2669. 10.1182/blood-2003-04-1078.
McGettrick AF, O’Neill LA: Localisation and trafficking of Toll-like receptors: an important mode of regulation. Curr Opin Immunol. 2010, 22: 20-27. 10.1016/j.coi.2009.12.002.
Gazi U, Rosas M, Singh S, Heinsbroek S, Haq I, Johnson S, Brown GD, Williams DL, Taylor PR, Martinez-Pomares L: Fungal recognition enhances mannose receptor shedding through dectin-1 engagement. J Biol Chem. 2011, 286: 7822-7829. 10.1074/jbc.M110.185025.